EP0953053A2 - Gegenüber dem zellrezeptor maskierte oder nicht-maskierte virenpartikeln - Google Patents
Gegenüber dem zellrezeptor maskierte oder nicht-maskierte virenpartikelnInfo
- Publication number
- EP0953053A2 EP0953053A2 EP97925095A EP97925095A EP0953053A2 EP 0953053 A2 EP0953053 A2 EP 0953053A2 EP 97925095 A EP97925095 A EP 97925095A EP 97925095 A EP97925095 A EP 97925095A EP 0953053 A2 EP0953053 A2 EP 0953053A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- peptide
- receptor
- terminal
- protein domain
- retro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000003612 virological effect Effects 0.000 title claims description 117
- 239000002245 particle Substances 0.000 title claims description 94
- 210000004027 cell Anatomy 0.000 claims abstract description 174
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 159
- 108020001580 protein domains Proteins 0.000 claims abstract description 88
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 67
- 150000001413 amino acids Chemical class 0.000 claims abstract description 66
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 64
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 58
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 55
- 230000003993 interaction Effects 0.000 claims abstract description 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 41
- 229920000037 Polyproline Polymers 0.000 claims abstract description 25
- 229920001184 polypeptide Polymers 0.000 claims abstract description 24
- 238000010276 construction Methods 0.000 claims abstract description 18
- 230000001413 cellular effect Effects 0.000 claims abstract description 16
- 108010026466 polyproline Proteins 0.000 claims abstract description 15
- 239000000427 antigen Substances 0.000 claims abstract description 7
- 108091007433 antigens Proteins 0.000 claims abstract description 7
- 102000036639 antigens Human genes 0.000 claims abstract description 7
- 230000005764 inhibitory process Effects 0.000 claims abstract description 4
- 230000002401 inhibitory effect Effects 0.000 claims abstract 2
- 108020003175 receptors Proteins 0.000 claims description 148
- 241000700605 Viruses Species 0.000 claims description 79
- 230000001177 retroviral effect Effects 0.000 claims description 65
- 230000008685 targeting Effects 0.000 claims description 64
- 101710121417 Envelope glycoprotein Proteins 0.000 claims description 59
- 239000002773 nucleotide Substances 0.000 claims description 53
- 125000003729 nucleotide group Chemical group 0.000 claims description 53
- 241000714177 Murine leukemia virus Species 0.000 claims description 44
- 230000007246 mechanism Effects 0.000 claims description 42
- 241000713869 Moloney murine leukemia virus Species 0.000 claims description 39
- 239000013598 vector Substances 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 36
- 230000000873 masking effect Effects 0.000 claims description 29
- 238000012546 transfer Methods 0.000 claims description 28
- 241001430294 unidentified retrovirus Species 0.000 claims description 28
- 108090000288 Glycoproteins Proteins 0.000 claims description 27
- 102000003886 Glycoproteins Human genes 0.000 claims description 27
- 230000006870 function Effects 0.000 claims description 26
- 230000008569 process Effects 0.000 claims description 26
- 230000004927 fusion Effects 0.000 claims description 25
- 239000003446 ligand Substances 0.000 claims description 23
- 108070000030 Viral receptors Proteins 0.000 claims description 22
- 101800000135 N-terminal protein Proteins 0.000 claims description 21
- 101800001452 P1 proteinase Proteins 0.000 claims description 21
- 241000713813 Gibbon ape leukemia virus Species 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 13
- 241000713877 Simian sarcoma-associated virus Species 0.000 claims description 11
- 238000004873 anchoring Methods 0.000 claims description 10
- 241000702421 Dependoparvovirus Species 0.000 claims description 9
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 8
- 239000003102 growth factor Substances 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 claims description 7
- 239000000813 peptide hormone Substances 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108010038988 Peptide Hormones Proteins 0.000 claims description 6
- 102000015731 Peptide Hormones Human genes 0.000 claims description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 5
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- 241001529453 unidentified herpesvirus Species 0.000 claims description 5
- 239000013603 viral vector Substances 0.000 claims description 5
- 241000714165 Feline leukemia virus Species 0.000 claims description 4
- 239000000833 heterodimer Substances 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 101000851056 Bos taurus Elastin Proteins 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 102100021696 Syncytin-1 Human genes 0.000 claims 13
- 241000206602 Eukaryota Species 0.000 claims 1
- 230000000799 fusogenic effect Effects 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract description 18
- 238000007514 turning Methods 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 description 117
- 235000001014 amino acid Nutrition 0.000 description 59
- 229940024606 amino acid Drugs 0.000 description 59
- 208000015181 infectious disease Diseases 0.000 description 51
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 49
- 101100356020 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) recA gene Proteins 0.000 description 48
- 101100042680 Mus musculus Slc7a1 gene Proteins 0.000 description 48
- 101800001707 Spacer peptide Proteins 0.000 description 44
- 239000012634 fragment Substances 0.000 description 44
- 239000013612 plasmid Substances 0.000 description 37
- 108020004414 DNA Proteins 0.000 description 26
- 210000002845 virion Anatomy 0.000 description 22
- 108091034117 Oligonucleotide Proteins 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 17
- 235000013930 proline Nutrition 0.000 description 17
- 230000002458 infectious effect Effects 0.000 description 16
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 15
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 13
- 238000001415 gene therapy Methods 0.000 description 12
- 125000006850 spacer group Chemical group 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 101150066555 lacZ gene Proteins 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- 108700004025 env Genes Proteins 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 102000001301 EGF receptor Human genes 0.000 description 8
- 108060006698 EGF receptor Proteins 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 101150030339 env gene Proteins 0.000 description 7
- 230000002185 fusiogenic effect Effects 0.000 description 7
- 210000005260 human cell Anatomy 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 238000004448 titration Methods 0.000 description 6
- 101710177291 Gag polyprotein Proteins 0.000 description 5
- 102000046255 Type III Sodium-Phosphate Cotransporter Proteins Human genes 0.000 description 5
- 108091006286 Type III sodium-phosphate co-transporters Proteins 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 description 4
- JCLFHZLOKITRCE-UHFFFAOYSA-N 4-pentoxyphenol Chemical compound CCCCCOC1=CC=C(O)C=C1 JCLFHZLOKITRCE-UHFFFAOYSA-N 0.000 description 4
- 241000713826 Avian leukosis virus Species 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 101710125418 Major capsid protein Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 description 4
- 108010035235 Phleomycins Proteins 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000005199 ultracentrifugation Methods 0.000 description 4
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 230000005017 genetic modification Effects 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 108010089520 pol Gene Products Proteins 0.000 description 3
- 108700004029 pol Genes Proteins 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241001128034 Amphotropic murine leukemia virus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 241001663880 Gammaretrovirus Species 0.000 description 2
- 102220541510 Golgi to ER traffic protein 4 homolog_D84K_mutation Human genes 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000016462 Phosphate Transport Proteins Human genes 0.000 description 2
- 108010092528 Phosphate Transport Proteins Proteins 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- -1 about 1 to 10) Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001295 alanines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 101150088264 pol gene Proteins 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000714235 Avian retrovirus Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101100118554 Homo sapiens EGF gene Proteins 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 241000244189 Lineus Species 0.000 description 1
- 208000033868 Lysosomal disease Diseases 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000714178 Mink cell focus-forming virus Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 241000714199 Myeloproliferative leukemia virus Species 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000002199 attachment cell Anatomy 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 108010083912 bleomycin N-acetyltransferase Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960002328 chloroquine phosphate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000007247 enzymatic mechanism Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 230000030414 genetic transfer Effects 0.000 description 1
- 108010084724 gibbon ape leukemia virus receptor Proteins 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003148 prolines Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 238000005829 trimerization reaction Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13061—Methods of inactivation or attenuation
- C12N2740/13062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6045—RNA rev transcr viruses
- C12N2810/6054—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/852—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from cytokines; from lymphokines; from interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/854—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from hormones
Definitions
- Retroviruses and therefore retroviral vectors initiate their infectious cycle by recognizing specific cell surface molecules, called retroviral receptors, with envelope glycoproteins expressed on the surface of retroviral particles. This recognition then leads to the fusion between the viral and cellular membranes, a complex and poorly understood process which is also mediated by a second function of the envelope glycoprotein.
- the present invention also relates to the construction of chimeric envelope glycoproteins using these new peptides.
- the invention relates to the use of a peptide for the transfer of genes into a target eukaryotic cell, which peptide has from approximately 10 to approximately 200, in particular from approximately 15 to approximately 150 amino acids, and advantageously approximately 20 amino acids, in which at least 30% of the amino acids consist of proline residues, which proline residues are regularly arranged so as to induce folds of the polypeptide chain at approximately 180 ° (" ⁇ -turn” or "reverse- turn "), these folds being regularly spaced and assembling in a polyproline helix with folding type ⁇ (" polyproline ⁇ -turn helix "), in a polypeptide construction containing, on the N-terminal side (upstream) of said peptide, an N-terminal (upstream) protein domain capable of recognizing a targeted surface molecule or an antigen expressed on a cell surface, in particular an appropriate receptor (targeted receptor) located on said cell
- this ⁇ -folded polyproline helix contains 4 ⁇ folds and therefore 4 turns, and is moreover incompatible with a secondary structure in ⁇ -helix or in ⁇ sheet.
- the ⁇ -folding polyproline helix placed between the two domains of the chimeric protein (N-terminal domain and auxiliary domain) intrinsically has, 1) an elastomeric force, 2) the property of self-assembling with other polyproline helices, probably in relation to the trimeric nature of the envelope, 3) the property of transmitting to the auxiliary domain a deformation induced by the binding of the N-terminal domain with its receptor, causing activation of the auxiliary domain .
- markers specifically present on various differentiated tissues (example: receptor for growth factors, peptide hormones).
- a targeted surface molecule As an example of a targeted surface molecule, mention may be made in particular of a receptor which will hereinafter be designated as a targeted receptor.
- substantially intact refers to a viral glycoprotein which retains all of its determinants necessary for preserving the post-translational processes, if necessary, the oligomerization, the viral incorporation and fusion properties.
- certain alterations can be made to the glycoprotein without significantly affecting these functions and the glycoproteins containing such minor modifications are considered to be substantially intact for the purposes of the invention.
- the glycoprotein may lack a few amino acids (e.g. about 1 to 10), especially at the N-terminus, but will generally be the same size as the wild type protein and has essentially the same biological properties than wild protein.
- non-viral recombinant gene transfer vector denotes macromolecular complexes associating the DNA containing the transferred gene, its expression regulation sequences, and molecules belonging to the class of lipids, carbohydrates, or proteins. , which have functional properties capable, 1) of targeting the deposition of DNA on the surface of the target cell, 2) of introducing this DNA into the target cell, and 3) of introducing this DNA into the nucleus of the target cell.
- the envelope glycoprotein comprising:
- the C-terminal (downstream) protein domain corresponds to a (retro) viral envelope glycoprotein, essentially intact, comprising the natural binding domain, the fusion and anchoring functions of the wild envelope glycoprotein from which the envelope glycoprotein carried by the recombinant (retro) viral particle is derived.
- N-terminal protein domain upstream of the above peptide, capable of reacting with an appropriate receptor (targeted receptor) located on a eukaryotic cell, which protein domain makes it possible to specifically bind a recombinant (retro) viral particle containing said protein domain N-terminal and
- MLV-A, GALV, FeLVB or viruses such as adenovirus, herpes virus, AAV virus (Adeno Associated Virus), or more generally viral glycoproteins derived from viruses of eukaryotic origin, in particular orthomyxovirus (such as influenza virus) or paramyxovirus (such as SV5).
- viruses such as adenovirus, herpes virus, AAV virus (Adeno Associated Virus), or more generally viral glycoproteins derived from viruses of eukaryotic origin, in particular orthomyxovirus (such as influenza virus) or paramyxovirus (such as SV5).
- the invention also relates to a recombinant (retro) viral particle characterized in that the 5 'end of the nucleotide sequence coding for the N-terminal (upstream) protein domain is contiguous with the 3' end of the nucleotide sequence coding for the signal peptide, the 3 'end of the nucleotide sequence coding for the N-terminal (upstream) protein domain is contiguous with the 5' end of the nucleotide sequence coding for the peptide, the 3 'end of the nucleotide sequence coding for the peptide is contiguous with the 5 ′ end of the nucleotide sequence coding for the C-terminal protein domain (downstream).
- the invention also relates to a nucleic acid coding for a peptide or for a recombinant particle according to the invention.
- the invention containing the nucleic acid to be transferred.
- the invention also relates to a pharmaceutical composition containing as active substance a (retro) v ⁇ rale particle according to the invention, and also containing a gene to be transferred, in association with a physiologically appropriate pharmaceutical vehicle.
- genes to be transferred which are important for gene therapy, these are for example IFN, IL2, p53, VEGF, TNF, CFTR, HSV-TK, lacZ, GFP, various cytokine genes, other types of suicide genes including conditional suicide genes, other genes with anti-viral activity, other genes with anti-tumor activity, other marker genes and any therapeutic gene for mono- or multi-gene disease.
- the pathologies most specifically concerned are: most single and multi-gene diseases (mucovisidosis, myopathy, lysosomal diseases, various forms of cancer, viral diseases (AIDS), ...)
- FIG. 1 shows the two-stage entry process of the targeting viral particle.
- the viral particles are generated (A) with targeting envelope glycoproteins composed of an N-terminal domain (ligand, monobrin antibody, etc.), of the masking / unmasking peptide, and of a C-terminal domain (B).
- the steps leading to the introduction of the virion into the targeted cell involve a mechanism coordinated by the masking / unmasking peptide (C).
- FIG. 2 is a schematic representation of some of the targeting envelopes studied. The position of some functional regions is shown. Vertical arrows: proteolytic cleavage sites.
- SU surface subunit
- TM transmembrane subunit
- SP signal peptide
- PRO poly-proline region
- T transmembrane domain
- Ram-1 ligand binding domain for the amphotropic receptor
- Rec-1 ligand binding domain for the ecotropic receptor
- EGF epidermal growth factor.
- Dark gray boxes sequence derived from the env gene of MoMLV
- Light gray boxes sequence derived from the env gene of MLV-4070A
- White boxes other sequences derived from MLV.
- Black boxes spacer peptides derived from the poly-proline region. All env genes are expressed from the same promoter (LTR) and polyadenylation signal (pA) from the subgenomic mRNA using the retroviral, donor (SD) and acceptor splice sites.
- LTR promoter
- SA SA with an identical intronic sequence of 190 nts containing the end of the pol gene ( ⁇ POL). The position of some restriction sites is shown.
- FIG. 5 shows the expression and viral incorporation of the chimeric envelopes of the AMO series.
- FIG. 7 shows the amino acid and nucleotide sequence of PRO (4070A).
- FIG. 9 shows the amino acid and nucleotide sequence of PRO ⁇ (MoMLV).
- FIG. 10 shows the amino acid and nucleotide sequence of
- FIG. 30 shows the amino acid and nucleotide sequence of AMOEL3.
- FIG. 35 shows the amino acid and nucleotide sequence of EL5.
- FIG. 36 shows the amino acid and nucleotide sequence of ⁇ PR04-beta.
- FIG. 39 shows the amino acid and nucleotide sequence of PRO-beta.
- FIG. 40 shows the amino acid and nucleotide sequence of PRO-int.
- Retroviruses use a number of cell surface molecules, called viral receptors, to initiate the infectious process (23). With notable exceptions, notably in the case of human immunodeficiency viruses, most of the receptors used by other retroviruses and in particular mammalian type C retroviruses are distributed on most cell types of the host organism. For example, the amphotropic murine leukemia virus (MLV-A) is capable of infecting most mammalian cells because its receptor, the phosphate transporter Ram-1, is expressed on almost all cells.
- MLV-A amphotropic murine leukemia virus
- polypeptides capable of binding various cell surface molecules have been inserted at the N-terminal end of the SU subunit of the envelope glycoprotein (6) (10) (13) (15) (21).
- the study of virions generated with these various types of targeting envelopes has shown that it is possible to specifically and effectively redirect the binding of viral particles to new surface molecules.
- Some factors that limit the effectiveness of targeting have also been identified. The first seems to depend on physiological properties of the targeted surface molecule (dimerization, internalization, intracellular transport process) (6), the second is linked to the low intrinsic fusiogenicity of the glycerol of envelope chimeras generated by insertion.
- N terminal ligands (6) (21).
- the natural binding domain of the support envelope is always functional.
- this functionality of the natural binding domain does not pose problems of infection "background noise” because the ecotropic envelope of the virus is used as the support glycoprotein.
- MoMLV which does not recognize a receptor on the cells of higher mammals.
- N-terminal targeting glycoprotein and then an auxiliary mechanism to facilitate the entry of the virus specifically linked to the right cellular target through the natural retroviral receptor.
- spacer masking / unmasking peptides have also been developed, inserted between the targeting domain and the glycoprotein of support envelope, and which are capable of masking the natural binding domain as long as the viral particle has not interacted with the targeted surface molecule. The realization of this interaction induces the unmasking of the natural binding domain and the interaction between the natural binding domain and the natural retroviral receptor (auxiliary mechanism) which then takes over to introduce the virus into the cell.
- the TELCeB ⁇ cell line (7) is derived from the TELacZ line (19) by transfection and clonal selection of cells expressing the gag and pol proteins of MoMLV (Moloney Murine Leukemia Virus: Moloney murine leukemia virus).
- TELacZ cells express the retroviral vector MFGnlslacZ capable of transducing a nuclear ⁇ -galactosidase.
- TELCeB ⁇ cells allow the production of retroviral capsids (non-infectious because they lack envelopes) carrying the retroviral marker vector nlsLacZ.
- the A431 (ATCC CRL1555) and TE671 (ATCC CRL8805) cells are cultured in DMEM medium (Gibco-BRL) supplemented with 10% fetal calf serum (Gibco-BRL).
- the CHO, CERD9 (9) and CEAR13 (9) cells are cultured in DMEM medium (Gibco-BRL) supplemented with 10% fetal calf serum and proline (Gibco-BRL).
- the NIH-3T3 and NIH-3T3 cell lines are cultured in DMEM medium (Gibco-BRL) supplemented with 10% newborn calf serum (Gibco-BRL). Chimerical envelopes. DNA fragments encoding polypeptides recognizing either EGFR
- the chimeric envelope is formed by cloning of the Xhol / Notl PCR fragment and of the Notl / Clal fragment, isolated from the env EMO gene (coding for the SU and TM-P15E transmembrane proteins of MoMLV), between the Xhol / Clal sites of the env 4070A MLV gene.
- the resulting constructs are recovered in the form of a BglII / ClaI fragment (corresponding to positions 5408 and 7676 in MoMLV) and cloned at the BamHI and ClaI sites of an expression plasmid FBMOSALF (7) in which a selection marker gene (8) fused to the polyadenylation sequences of the PGK (phospho-glycerate kinase) gene was introduced downstream of the 3 'LTR of the MLV-C57 virus.
- a selection marker gene (8) fused to the polyadenylation sequences of the PGK (phospho-glycerate kinase) gene was introduced downstream of the 3 'LTR of the MLV-C57 virus.
- the new recognition domain was separated from the rest of the MLV envelope by a spacer peptide consisting of three alanines, provided by the Notl cloning site (15).
- spacer amino acids were introduced either after the domain of EGFR recognition (EGF), either after the Ram-1 recognition domain (AS208) as described below.
- AMOl the first 208 amino acids, derived from the envelope of MLV 4070 A, were fused to amino acid 1 of the SU of MoMLV.
- AMOlFx a site of 4 amino acids corresponding to the cleavage site of blood coagulation factor Xa (Ile-Glu-Gly-Arg) (12) was inserted after the recognition domain of Ram-1 and fused to codon + 1 of MoMLV's SU. The strategy used for these constructions is described above.
- an oligonucleotide (5'-TCCAATTCCTTCCAAGGGGC-3 '), located just upstream of the Xhol site of the env gene of 4070A (nt 594) was used in combination with either one of the following two oligonucleotides providing Notl site:
- PCR fragments were subjected to digestion with Xhol and NotI and cloned into the plasmid FBAMOSALF opened in Xhol / NotI, a plasmid expressing an envelope of AMO type.
- the plasmids expressing the AMOFx, AMOl and AMOlFx envelopes were generated by cloning the NdeI / NotI fragment of FBAMOSALF (comprising the recognition domain Ram-1) in a series of plasmids (13) expressing the MoMLV envelopes modified in order to create a site Notl at codon 1 or codon 6 with (AMOlFx, AMOFx) or without (AMOl) the sequence Xa.
- Envelopes derived from AMO and containing other types of spacer peptides were constructed. All of these spacer peptides are shown in Figure 3 A.
- 3 'fragments were generated by PCR using the MoMLV env gene as a template, as a 5' oligonucleotide (5 '-ACTGGGGCTTACGTTTGT-3') upstream of the BamHI site, and as a 3 'oligonucleotide (5' -TATGTGCGGCCGCCGGTGGAAGTTGGGTAGGG- ') or (5' -TATGTGCGGCCGCGTCTGGCAGAACGGGGTTTGG-3 ') to build the MOAPRO and MOA ⁇ PRO envelopes, respectively.
- These PCR fragments were digested with BamHI and NotI, and co-ligated with the 5 'fragment.
- the sequence of spacer peptides for these two constructs is shown in Figure 3B.
- plasmids expressing the EMOI and EMOlFx envelopes were generated.
- the sequence of spacer peptides. for these two constructions is shown in Figure 3C.
- the plasmids expressing the EAPRO + and EA ⁇ PRO + envelopes were generated by replacing the Sfil / Not fragment of the FBEASALF plasmid by the Sfil / Notl fragments derived from the plasmids expressing the EMOPRO + and EMO ⁇ PRO + envelopes.
- the virus-producing cells are lysed for 10 min at 4 ° C. in 20 mM Tris-HCL buffer (pH 7.5), containing 1% tritonXIOO, 0.05% SDS, 5 mg / ml deoxycholate, 150 mM NaCl and PMSF
- Target cells were washed with PBS and detached by incubation
- the target cells are incubated for 30 min at 37 ° C. in a medium containing 10 ⁇ 6 M of recombinant human EGF (236-EG, R&D Systems, UK). The cells are then rinsed and the infections carried out as previously described. In order to block the acidification of the endosomes, 100 mM of chloroquine phosphate (Sigma, UK) is added to the medium. Six hours after infection, the cells are rinsed and incubated in a normal medium. Results and discussion.
- a first envelope targeting Ram-1, AMO was constructed by N-terminal insertion of the MoMLV envelope (by fusion with codon 7) of a polypeptide recognizing Ram-1 (AS208, FIG. 3 A) and corresponding to the first 208 amino acids of the SU of MLV-A (1).
- the sequence coding for EGF was inserted into the env gene of MLV at position +6 of the SU of
- the new binding domains were separated from the recognition domain of the retroviral receptor by a spacer peptide corresponding to three alanines.
- various constructions were then generated by insertion of spacers of different sizes and structures. The protein sequences of these different spacers are reported in Figure 3 A for the envelopes targeting Ram-1 and in Figure 3C for the envelopes targeting EGFR.
- the plasmids expressing the various envelopes were transfected into the TELCeB ⁇ cell line which expresses the proteins coded by the gag and pol genes, as well as a retroviral vector nlsLacZ ( 7).
- Cell surface expression was determined by FACS analysis of producer cells, using antibodies against SU, or using anti-EGF monoclonal antibody.
- the cells transfected with the different envelopes can be labeled with the anti-SU antibody (not shown).
- Only cells expressing EGF fusion envelopes can be labeled using anti-EGF monoclonal antibodies ( Figure 4). This demonstrates the expression of the chimeric envelopes on the cell surface and the correct folding of the EGF on the chimeric glycoproteins.
- Envelopes targeting EGFR are also capable of binding to A431 cells, over expressing EGFR ( Figure 6A). This connection seems specific since a pre-incubation of A431 cells in the presence of EGF (inducing the endocytosis of EGFR) inhibits this binding (not shown). Ram-1 and Rec-1 cooperation in infection.
- the transduction of the pseudotyped retroviral vectors by the various targeting envelopes was measured on cells expressing different types of receptors: human TE671 cells expressing the EGF receptors and
- Viruses with AMO chimeric envelopes are capable of infecting TE671 cells in a titer of 4.10 ⁇ lacZ i.u./ml (Table 1). In comparison; despite a similar receptor binding efficiency ( Figure 6B), the titers obtained with wild envelopes are 10,000 times higher. Su ⁇ renantly, the viruses expressing AMOPRO envelopes, despite good binding efficiency, have been found incapable of infecting human TE671 cells.
- Viruses carrying the chimeric envelopes in which the Ram-1 binding domain has been separated from the SU of MoMLV by different spacers prove to be very infectious on 3T3 cells.
- an increase from 200 (for AMOPRO) to more than 1000 times (for AMOlFx) of the viral titers was measured (Table 1).
- the virions containing the AMO ⁇ PRO envelope can effectively infect cells when Ram-1 is expressed there alone.
- the infectivity is increased by approximately 10 times when Rec-1 is also present on the cell surface. This difference is not due to the simple fact that AMO ⁇ PRO virions preferentially use Rec-1 for infection.
- infection of cells on which only Rec-1 is available is extremely low (Table 1) or even undetectable (Table 2) compared to when Ram-1 and Rec-1 are co-expressed.
- the RecID index is less than 10 ⁇ 5 (Table 2). This also demonstrates that the two receptors can synergize the infection.
- the AMO ⁇ PRO virions are compared to the virions containing the envelopes with the flexible spacers AMOlFx, AMOGIFx and AMOG2.
- the ⁇ PRO peptide is contains 5 prolines probably arranged in a polyproline type II helix, while the AMOGIFx and AMOG2 envelopes essentially contain glycines.
- virions containing AMOPRO envelopes require the simultaneous presence of both types of receptors to infect cells.
- the infectious titer in cell types co-expressing the two receptors is however lower than that which is observed with the AMO ⁇ PRO virions, without however excluding the hypothesis that the slightest inco deoration of these envelopes is responsible for this result.
- AMOPRO viruses cannot infect cells when either of the two receptors is expressed alone (Table 2).
- the two indices RamID and RecID are indeed lower than A.
- MOAPRO envelopes include the binding domain of the ecotropic envelope followed by the proline region rich in this same envelope, all fused to the N-terminal end of the amphotropic envelope ( Figure 2).
- Table 2 The results, shown in Table 2, indicate that, similarly to the virions containing the AMOPRO envelopes, the MOAPRO virions can hardly, if at all, infect cells expressing only one or the other of the Rec-1 receptors or Ram-1.
- the Ram-1 field in the MOAPRO envelope is even less accessible (Ramid less than 7xl0 "5) than the field is the Rec-1 in AMOPRO envelope (RECID less than 5, 6x10-4
- the MOAPRO envelopes can effectively infect cells expressing the two types of receptors, with titers of the order of 10 ⁇ lacZ iu / ml, suggesting that, in the case of this envelope too, the presence of the two receptors synergizes the infectious process.
- the spacer peptide inserted between the targeting domain and the rest of the retroviral envelope exerts a control on the accessibility of the domain located downstream of said peptide and on the activation of the fusion. This control depends on the peptide itself and is influenced by its length and by its biochemical composition.
- the hypothesis formulated is that the spacer peptide PRO would ultimately play the same role as the proline-rich region from which it originates and which is located, in the unmodified glycoprotein, between the receptor binding domain and the fusion domain. This role would be the masking of the downstream domain (fusion domain for the wild envelope or binding domain for the chimeric envelope) and the unmasking following the interaction of the upstream domain with its receptor.
- this unmasking would lead to activation of the fusion, while in the case of chimeric envelopes, the unmasking would lead to the accessibility of the binding domain to the viral receptor. If the receptor is expressed on the cell surface, there can then be interaction, this then triggering the activation of the fusion domain explaining why the simultaneous presence of the two receptors synergizes the infection.
- a targeting envelope in two stages for which a targeting envelope is constructed with different domains whose functions are activated and coordinated by means of specific spacer peptides containing sequences rich in proline.
- These chimeric envelope glycoproteins can be designed in the following way, with from N-terminal to C-terminal, a "targeting" domain capable of recognizing a cell surface molecule specifically expressed on the targeted tissue or cell (for example a single chain antico ⁇ s or a ligand for a surface receptor); a spacer peptide capable of masking an auxiliary domain itself capable of facilitating the penetration of the virus when it is activated.
- auxiliary domain can be an entire retroviral envelope, i.e.
- the helper domain should be masked until the virus particle has specifically interacted with the targeted surface molecule.
- the targeted surface molecule is Ram-1 while the auxiliary domain is the ecotropic envelope. EGFR and Rec-1 cooperation in infection.
- the targeting domain is EGF
- the auxiliary domain is the ecotropic envelope.
- the infection tests were carried out with cells expressing Rec-1 only (Cerd9 cells) or with cells co-expressing Rec-1 and EGFR (3T3 cells). The results of a typical experiment are reported in Table 3. As expected by the results obtained with the AMO envelopes, viruses containing the EMO envelopes can effectively infect Cerd9 and 3T3 cells, indicating that the Rec- binding domain 1 in these envelopes is not hidden. Compared to EMO viruses, viral particles containing the EMOPRO + and EMO ⁇ PRO + envelopes can only with difficulty infect Cerd9 cells (between 1,000 and 10,000 times worse than EMO viruses).
- the viral particles containing the EMOPRO + and EMO ⁇ PRO + envelopes are 20 and 60 times more infectious, respectively, compared to when Rec-1 is expressed alone.
- the masking is apparently less successful, and this results in significant infectivity on Cerd9 cells. This may be due to the fact that the spacer peptides PRO + and ⁇ PRO + are not optimized for their function, but perhaps also to the fact that the Cerd9 cells express a little EGF receptor which would help activate the EMOPRO + and EMO ⁇ envelopes PRO +.
- a percentages calculated taking as values 100 the titers obtained on 3T3 b: infection on 3T3 chronically infected with MLV-A (3T3-MLV-A) or with MoMLV (3T3-MoMLV) c: receptor available on the surface of the cell considered
- EXAMPLE 2 In order to characterize the cooperation between the Rec-1 and Ram-1 receptors, as well as the peptides capable of regulating this cooperation of receptors, a new series of AMO-type chimeric envelope glycoproteins (see previous example) a been built - in order to check whether the infection obtained with the AMOPRO and AMODeltaPRO envelopes passes, in a second step, through an interaction with Rec-1, the binding site with Rec-1 was inactivated by point mutagenesis (D84K mutation) (MacKrell et al.,]. Virology, 70: 1768-1774.
- the AMOEL3 and AMOEL5 envelopes were constructed. These envelopes respectively carry 3 and 5 turns of a type II polyproline helix characterized in the literature (Urry, Journal of Protein Chemistry 7: 1-34. (1988)).
- Retroviruses were generated with these chimeric envelopes and were characterized by infection of cells expressing either Rec-1 alone, or Ram-1 alone, or the two molecules Ram-1 and Rec-1.
- oligonucleotides elast3U (5'-TTT ATG GTC ACC GCG GCC GCA CCT GGG GTA GGG GCT CCG GGG GTA GGG GCT CCT GGG GTG GCC ATA TAA) and elast3L (5'-TTA TAT GGC CAC CCC AGG AGC CCC TAC
- the oligonucleotides UpE15 (5 * -G AT GTA CCT GGG GTA GGC GCC CCT GGA GTC GGG GCT CCT GGG GTA GGA TTC AT) and LowE15: (5 '-ATG AAT CCT ACC CCA GGA GCC CCG ACT CCA GGG GCG CCT
- the DELASTIN3-V Upper oligonucleotides (5'-GTC ACC GCG GCC GTC CCT GGG GTA GGG GTG CCG GGG GTA GGG GTG CCT GGG GTG GCC ATA TA A) and DELASTIN3-V Lower (5'-TTA TAT GGC CAC CCC AGG CAC CCC TAC CCC CGG CAC CCC TAC CCC AGG GAC GGC CGC GGT GAC) have been hybridized.
- the resulting double-stranded DNA fragment was digested with the restriction enzyme Eael and cloned into the expression plasmid FBAMOSALF previously opened in NotI. This results in the plasmid
- FBAMOEL3-VSALF (see sequence of the AMOEL3-V gene in FIG. 34) comprising the peptide EL3-V whose peptide sequence is represented in table 4 (see nucleotide sequence in FIG. 35).
- FBAMOEL3-ISALF comprising the peptide EL3-I whose peptide sequence is represented in table 4.
- Expression and viral inco ⁇ oration of chimeric envelopes Expression plasmids for the envelopes AMO, AMODeltaPRO, AMOPRO, AMOEL3, AMOEL5, AMOEL3-V, AMOEL3-I, AMOIFX, AMOG1X, AMOD84K, AMODeltaPROD84K, AMOPROD84K, AMOG1XD84K, AMODeltaPR02
- the corresponding DNA fragments were digested with the enzyme EagI and separately inserted into the plasmid FBEASALF (expressing the chimeric envelope glycoproteins EA) (Cosset et al., Journal of Virology 69: 6314-6322.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9606234A FR2748747B1 (fr) | 1996-05-20 | 1996-05-20 | Particules virales recombinantes comportant un peptide ayant des proprietes de masquage et de demasquage vis-a-vis d'un mecanisme biologique |
FR9606234 | 1996-05-20 | ||
PCT/FR1997/000870 WO1997044474A2 (fr) | 1996-05-20 | 1997-05-16 | Particules virales masquees ou demasquees vis-a-vis du recepteur cellulaire |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0953053A2 true EP0953053A2 (de) | 1999-11-03 |
Family
ID=9492280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97925095A Withdrawn EP0953053A2 (de) | 1996-05-20 | 1997-05-16 | Gegenüber dem zellrezeptor maskierte oder nicht-maskierte virenpartikeln |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0953053A2 (de) |
JP (1) | JP2000511051A (de) |
AU (1) | AU725632B2 (de) |
CA (1) | CA2253874A1 (de) |
FR (1) | FR2748747B1 (de) |
WO (1) | WO1997044474A2 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2773561A1 (fr) * | 1998-01-15 | 1999-07-16 | Centre Nat Rech Scient | Utilisation d'une sequence riche en proline pour augmenter le caractere fusogenique d'enveloppes de retrovirus |
WO2000071578A2 (en) * | 1999-05-20 | 2000-11-30 | Cnrs Centre National De La Recherche Scientifique | New polypeptides and their use for the rescue of fusion defective virus or retrovirus glycoproteins |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0365655B1 (de) * | 1988-04-21 | 1994-09-21 | Uab Research Foundation | Bioelastomer ohne adhäsionseigenschaft zum einsatz am wundort |
US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
JP3533219B2 (ja) * | 1992-11-09 | 2004-05-31 | アメリカ合衆国 | 標的指向ベクター粒子 |
US5773577A (en) * | 1994-03-03 | 1998-06-30 | Protein Polymer Technologies | Products comprising substrates capable of enzymatic cross-linking |
GB9412844D0 (en) * | 1994-06-27 | 1994-08-17 | Medical Res Council | Improvements in or relating to therapeutic methods |
US5662885A (en) * | 1994-07-22 | 1997-09-02 | Resolution Pharmaceuticals Inc. | Peptide derived radionuclide chelators |
-
1996
- 1996-05-20 FR FR9606234A patent/FR2748747B1/fr not_active Expired - Fee Related
-
1997
- 1997-05-16 WO PCT/FR1997/000870 patent/WO1997044474A2/fr not_active Application Discontinuation
- 1997-05-16 AU AU30356/97A patent/AU725632B2/en not_active Ceased
- 1997-05-16 CA CA002253874A patent/CA2253874A1/en not_active Abandoned
- 1997-05-16 EP EP97925095A patent/EP0953053A2/de not_active Withdrawn
- 1997-05-16 JP JP09541705A patent/JP2000511051A/ja active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO9744474A2 * |
Also Published As
Publication number | Publication date |
---|---|
JP2000511051A (ja) | 2000-08-29 |
AU725632B2 (en) | 2000-10-19 |
CA2253874A1 (en) | 1997-11-27 |
AU3035697A (en) | 1997-12-09 |
WO1997044474A2 (fr) | 1997-11-27 |
FR2748747A1 (fr) | 1997-11-21 |
WO1997044474A3 (fr) | 1998-03-05 |
FR2748747B1 (fr) | 1998-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Romano et al. | Gene transfer technology in therapy: current applications and future goals | |
Cosset et al. | High-titer packaging cells producing recombinant retroviruses resistant to human serum | |
EP0840797B1 (de) | Verfahren und mittel zur gezielten freisetzung von genen | |
US5869331A (en) | Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins | |
US6534051B1 (en) | Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins | |
WO1996001324A2 (fr) | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique | |
JPH09509329A (ja) | 遺伝子搬送媒体を標的とする組成物及び方法 | |
WO1996004934A1 (en) | Retroviral vectors produced by producer cell lines resistant to lysis by human serum | |
WO1994012626A1 (en) | Cell-type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins | |
US5858743A (en) | Delivery of nucleic acids | |
US6448390B1 (en) | Stable envelope proteins for retroviral, viral and liposome vectors and use in gene drug therapy | |
WO1995023846A1 (en) | Cell-type specific gene transfer using retroviral vectors containing antibody-envelope and wild-type envelope-fusion proteins | |
US8052966B2 (en) | Methods and compositions for treating metastatic cancer | |
WO1997044474A2 (fr) | Particules virales masquees ou demasquees vis-a-vis du recepteur cellulaire | |
CA2317026A1 (fr) | Utilisation d'une sequence riche en proline pour augmenter le caractere fusogenique d'enveloppes de retrovirus | |
EP0817860B1 (de) | Pseudotypisierte retrovirale vektoren | |
Romano et al. | Gene transfer technology in therapy: current applications and future goals | |
JP2005532075A (ja) | 改変した細胞結合活性を有するウィルス粒子の調製方法およびその使用 | |
FR2727429A1 (fr) | Lignees d'encapsidation et vecteurs d'expression pour la transcomplementation de vecteurs retroviraux defectifs | |
EP1006123A2 (de) | Hüllproteine, Verfahren und Anwendungen | |
Chowdhury | Retroviral targeting to tumour antigens | |
CA2524892A1 (en) | A purified polypeptide, isolated nucleic acids encoding said polypeptide, vectors and use thereof | |
Yee | Prospects for using retroviral vectors for human gene therapy | |
AU2004232328B2 (en) | Methods and compositions for treating disorders | |
AU2004232328C1 (en) | Methods and compositions for treating disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19981111 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20030925 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040206 |